by University of Maryland Computer simulation methods developed by Pratyush Tiwary’s lab identified two optimum pathways that Gleevec, a cancer drug, could take to unbind from the protein. The “fast” pathway allows Gleevec to leave the protein three times faster than that of the “slow” pathway, ultimately leading to drug resistance. Credit: Pratyush Tiwary Imatinib,...
